2375 related articles for article (PubMed ID: 17548456)
1. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.
Stürenburg E; Lang M; Horstkotte MA; Laufs R; Mack D
J Antimicrob Chemother; 2004 Nov; 54(5):870-5. PubMed ID: 15471997
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
4. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
5. Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.
Mushtaq S; Hope R; Warner M; Livermore DM
J Antimicrob Chemother; 2007 May; 59(5):1025-30. PubMed ID: 17353220
[TBL] [Abstract][Full Text] [Related]
6. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms.
Livermore DM; Mushtaq S; Warner M
J Antimicrob Chemother; 2009 Aug; 64(2):330-5. PubMed ID: 19497942
[TBL] [Abstract][Full Text] [Related]
7. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
Livermore DM; Hope R; Mushtaq S; Warner M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
[TBL] [Abstract][Full Text] [Related]
8. Cefdinir: in vitro activity study and effect of human serum.
García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.
Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D
J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
13. Combination of altered PBPs and expression of cloned extended-spectrum beta-lactamases confers cefotaxime resistance in Haemophilus influenzae.
Bozdogan B; Tristram S; Appelbaum PC
J Antimicrob Chemother; 2006 Apr; 57(4):747-9. PubMed ID: 16492720
[TBL] [Abstract][Full Text] [Related]
14. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
15. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
Livermore DM; Mushtaq S; Nguyen T; Warner M
Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
[TBL] [Abstract][Full Text] [Related]
16. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
Mushtaq S; Warner M; Williams G; Critchley I; Livermore DM
J Antimicrob Chemother; 2010 Jul; 65(7):1428-32. PubMed ID: 20478991
[TBL] [Abstract][Full Text] [Related]
17. Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae.
Shi WF; Zhou J; Qin JP
Chin Med J (Engl); 2009 May; 122(9):1092-6. PubMed ID: 19493446
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
19. Extended double disc synergy testing reveals a low prevalence of extended-spectrum beta-lactamases in Enterobacter spp. in Vienna, Austria.
Apfalter P; Assadian O; Daxböck F; Hirschl AM; Rotter ML; Makristathis A
J Antimicrob Chemother; 2007 May; 59(5):854-9. PubMed ID: 17347178
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of oral cephalosporin BAY v 3522 compared with other oral cephalosporins.
Locher R; Strässle A; Kayser FH
Drugs Exp Clin Res; 1990; 16(10):515-25. PubMed ID: 2100734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
